The price of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares last traded on Wall Street rose 0.11% to $4.39.
RXRX stock price is now -14.79% away from the 50-day moving average and -32.77% away from the 200-day moving average. The market capitalization of the company currently stands at $1.79B.
With the price target of $8, Morgan Stanley recently initiated with Equal-Weight rating for Recursion Pharmaceuticals Inc (NASDAQ: RXRX). On March 16, 2023, Needham recently initiated its ‘Buy’ rating on the stock quoting a target price of $17, while ‘KeyBanc Capital Markets’ rates the stock as ‘Overweight’
In other news, Gibson Christopher, Chief Executive Officer sold 138,574 shares of the company’s stock on Mar 27 ’25. The stock was sold for $836,987 at an average price of $6.04. Upon completion of the transaction, the Chief Executive Officer now directly owns 1,117,450 shares in the company, valued at $4.91 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 27 ’25, Officer Gibson Christopher bought 138,574 shares of the business’s stock. A total of $836,987 was incurred on buying the stock at an average price of $6.04. A total of 23.55% of the company’s stock is owned by insiders.
During the past 12 months, Recursion Pharmaceuticals Inc has had a low of $3.79 and a high of $12.36. As of last week, the company has a debt-to-equity ratio of 0.10, a current ratio of 4.11, and a quick ratio of 4.11.
The net profit margin was -961.32% and return on equity was -86.10% for RXRX. The company reported revenue of $14.74 million for the quarter, compared to $13.79 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 6.89 percent. For the current quarter, analysts expect RXRX to generate $16.23M in revenue.
